Panel Discussion: Monoclonals, Topicals, Orals, Targets, Mild Disease & More – Where Are the Industry’s Priorities to Develop Safe Therapies with Superior Efficacy?
Time: 9:30 am
day: Conference Day One
Details:
- With a rich pipeline of drugs targeting various inflammatory mechanisms, for different indications and leveraging different approaches, what will be the next blockbuster drug to reach the market?
- How are safety concerns around systemics and efficacy challenges around topicals being addressed, amidst regulatory and reimbursement environments?
- Faced with varying challenges to demonstrating clinical superiority and market acceptance, what does this mean for patients and the direction of pipelines today?
